Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5974602 | 0.97 | KDM4E (0.32) | KDM4EKMT2AGAATDP1MEN1 | |
| SCHEMBL17975271 | 0.89 | MEN1 (0.32) | KDM4EKMT2AMEN1LMNANPSR1 | |
| Hydrochloric Acid SCHEMBL8434379 | 0.86 | KMT2A (0.44) | KDM4EKMT2AGAATDP1MEN1 | |
| SCHEMBL7339174 | 0.75 | KDM4E (0.31) | KDM4E | |
| SCHEMBL11630899 | 0.68 | — | — | |
| SCHEMBL11681383 | 0.66 | KDM4E (0.35) | KDM4EKMT2AGAATDP1MEN1 | |
| SCHEMBL4100479 | 0.65 | KMT2A (0.52) | KDM4EKMT2AGAATDP1MEN1 | |
| SCHEMBL941085 | 0.64 | KMT2A (0.55) | KDM4EKMT2AGAAMEN1LMNA | |
| SCHEMBL9356896 | 0.64 | KDM4E (0.52) | KDM4EKMT2AGAATDP1MEN1 | |
| SCHEMBL14567641 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | claimed |
| US-20160374997-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-12-29 | — | — | US | disclosed |
| US-20160220510-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-08-04 | — | — | US | disclosed |
| US-20160220510-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-08-04 | — | — | US | disclosed |
| US-6689777-B2 | DEPOLYMERIZING HEMOZOIN USING 2-IMINO-NAPHTHO(1,2-D)THIAZOL-5-OL DERIVATIVES | KENNETH S. WARREN INSTITUTE | 2004-02-10 | — | — | US | disclosed |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374997-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | AARS1, EPRS1, EEF1G | KDM4E 1642/4885KMT2A 2096/4885GAA 836/4885 |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | TYR, CRYZ, RHOT2 | KDM4E 1240/4885KMT2A 2497/4885GAA 260/4885 |
| US-20160220510-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | AARS1, EPRS1, EEF1G | KDM4E 1642/4885KMT2A 2096/4885GAA 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.